tiprankstipranks
MustGrow Biologics (TSE:MGRO)
:MGRO
Want to see TSE:MGRO full AI Analyst Report?

MustGrow Biologics (MGRO) AI Stock Analysis

19 Followers

Top Page

TSE:MGRO

MustGrow Biologics

(MGRO)

Select Model
Select Model
Select Model
Underperform 40 (OpenAI - 5.2)
Rating:40Underperform
Price Target:
C$0.36
▼(-26.33% Downside)
Action:Downgraded
Date:07/08/26
The score is constrained primarily by weak financial performance—sharp TTM revenue decline, very large operating/net losses, and ongoing negative operating and free cash flow—despite only moderate leverage. Technicals add pressure with a clear downtrend (price below key moving averages and negative MACD), while oversold readings slightly temper the near-term risk. Valuation is not supportive because the company is loss-making (negative P/E) and no dividend yield is provided.
Positive Factors
Plant-based biologics focus
MustGrow’s core focus on mustard-derived and plant-based crop protection aligns with long-term structural demand for sustainable agricultural inputs. This differentiated technology base supports regulatory and partner-led commercialization paths, enabling persistent market relevance as farms shift toward biologics over several years.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow materially depletes liquidity and forces dependence on external funding or asset sales. Over a multi-month horizon this constrains R&D, regulatory work and commercial rollout, increasing dilution or debt risk and making execution on long-term plans more uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Plant-based biologics focus
MustGrow’s core focus on mustard-derived and plant-based crop protection aligns with long-term structural demand for sustainable agricultural inputs. This differentiated technology base supports regulatory and partner-led commercialization paths, enabling persistent market relevance as farms shift toward biologics over several years.
Read all positive factors

MustGrow Biologics (MGRO) vs. iShares MSCI Canada ETF (EWC)

MustGrow Biologics Business Overview & Revenue Model

Company Description
MustGrow Biologics Corp. is an agricultural biotechnology enterprise specializing in the creation and commercialization of natural crop protection solutions. These offerings, including biopesticides, biofumigants, and bioherbicides, are uniquely d...
How the Company Makes Money
null...

MustGrow Biologics Financial Statement Overview

Summary
Fundamentals are weak: revenue fell sharply TTM (~44% decline to ~$4.6M), profitability is deeply negative (TTM EBIT margin ~-78%, net margin ~-88%), and cash burn persists (TTM operating cash flow about -$3.8M; free cash flow about -$5.3M). The balance sheet is only moderately levered (debt-to-equity ~0.67), but equity has eroded substantially over time, increasing financial risk.
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
14
Very Negative
BreakdownMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue8.29M398.02K4.71M6.48K12.87K
Gross Profit1.41M300.75K4.33M6.48K12.87K
EBITDA-6.20M-4.89M-676.94K-5.56M-3.01M
Net Income-7.26M-4.89M-676.94K-5.57M-3.06M
Balance Sheet
Total Assets3.09M5.42M6.94M7.13M9.70M
Cash, Cash Equivalents and Short-Term Investments918.77K3.00M6.82M7.02M9.62M
Total Debt584.13K517.99K759.33K759.33K749.27K
Total Liabilities2.23M3.25M1.35M1.90M1.25M
Stockholders Equity867.10K2.17M5.58M5.24M8.46M
Cash Flow
Free Cash Flow-6.56M-3.58M-294.76K-3.26M-2.41M
Operating Cash Flow-5.06M-3.58M-294.76K-3.26M-2.41M
Investing Cash Flow-1.50M0.000.000.000.00
Financing Cash Flow4.48M-241.34K95.75K653.75K8.72M

MustGrow Biologics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.49
Price Trends
50DMA
0.47
Negative
100DMA
0.51
Negative
200DMA
0.59
Negative
Market Momentum
MACD
-0.03
Negative
RSI
40.28
Neutral
STOCH
71.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MGRO, the sentiment is Negative. The current price of 0.49 is above the 20-day moving average (MA) of 0.40, above the 50-day MA of 0.47, and below the 200-day MA of 0.59, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 40.28 is Neutral, neither overbought nor oversold. The STOCH value of 71.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MGRO.

MustGrow Biologics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
C$46.31B13.899.48%3.52%8.02%363.69%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
61
Neutral
C$36.35M17.6512.97%9.98%101.08%
46
Neutral
C$45.15M-3.79-49.69%-20.39%1.91%
42
Neutral
C$51.49M-33.82-24.54%45.16%
40
Underperform
C$24.55M-3.10-459.98%10.13%-14.94%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:MGRO
MustGrow Biologics
0.38
-0.46
-55.03%
TSE:PLAN
Progressive Planet Solutions Inc
0.33
0.11
50.00%
TSE:BEE
Bee Vectoring Technologies International
0.01
0.00
0.00%
TSE:GSP
Gensource Potash
0.12
0.04
53.33%
TSE:NPK
Verde Agritech
0.82
0.19
30.16%
TSE:NTR
Nutrien
95.99
18.66
24.13%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2026